1.
选择性奥希替尼研究的临床结果
Efficacy outcomes in selected osimertinib studies
| Study | Ref. | Phase | Treatment | ORR（%） | DCR (%) | PFS (mon) | |||||
| T790M+ | T790M- | T790M+ | T790M- | T790M+ | T790M- | ||||||
| DCR: disease control rate; NA: not applicable; ORR: objective response rate; PFS: progression-free survival; TKI: tyrosine kinase inhibitor. | |||||||||||
| AURA | Janne | Ⅰ/Ⅱ | Osimertinib | 61 | 21 | 95 | 61 | 9.6 | 2.8 | ||
| AURA extension | Yang | Ⅱ | Osimertinib | 62 | NA | 90 | NA | 12.3 | NA | ||
| AURA 2 | Goss | Ⅱ | Osimertinib | 70 | NA | 92 | NA | 9.9 | NA | ||
| AURA 3 | Mok | Ⅲ | Osimertinib or platinum-pemetrexed +/-maintenance pemetrexed |
71 31 |
NA NA |
93 | NA | 10.1 4.4 |
NA NA |
||